Back to today’s briefing

Story perspectives

FDA Cancels Flu Vaccine Meeting, Sparks Public Health Fears

2/28/2025

42 7

Summary

Story summary

The FDA's abrupt cancellation of its March 13 meeting on the 2025-26 flu vaccine strains has sparked alarm as the U.S. grapples with a harsh flu season. Experts fear that this delay could jeopardize vaccine production and public health. While the agency intends to issue guidance to manufacturers, the absence of expert insights raises significant concerns.

1 of 1

Story summary

The FDA's abrupt cancellation of its March 13 meeting on the 2025-26 flu vaccine strains has sparked alarm as the U.S. grapples with a harsh flu season. Experts fear that this delay could jeopardize vaccine production and public health. While the agency intends to issue guidance to manufacturers, the absence of expert insights raises significant concerns.